Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACT01 · 1 trial · 1 indication
Treatment success at end of study visit defined as % of participants with 100% clearance of AK lesions
| Arm | Type | Description |
|---|---|---|
| ACT01 plus Comp01 | PLACEBO_COMPARATOR | ACT01 Cream in combination with Comp01 Cream, once daily, 29 days |
| ACT01 plus Comp02 | ACTIVE_COMPARATOR | ACT01 Cream in combination with Comp02 Cream, once daily, 29 days |
| ACT01 plus Comp03 | ACTIVE_COMPARATOR | ACT01 Cream in combination with Comp03 Cream, once daily, 29 days |
| ACT01 plus Comp04 | OTHER | ACT01 Cream in combination with Comp04 Cream, once daily, 29 days |
| Name | Type | Description |
|---|---|---|
| ACT01 | DRUG | - |
| Comp01 | DRUG | - |
| Comp02 | DRUG | - |
| Comp03 | DRUG | - |
| Comp04 | DRUG | - |
Inclusion Criteria: 1. Presence of actinic keratosis lesions on the face and/or scalp within a 25 cm2 contiguous area containing at least four lesions that are non-hypertrophic and non-hyperkeratotic and not larger than 6 mm in longest diameter. 2. Age 30-85 years, inclusive. 3. Good general health...
ACT01 is an investigational small molecule being developed for the treatment of actinic keratosis, a skin condition characterized by rough, scaly patches on the skin caused by sun damage. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ACT01 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the safety and efficacy of ACT01 in patients with actinic keratosis.
ACT01 is currently in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not been approved for commercial use. Further clinical studies may be required to establish its safety and effectiveness.
ACT01 has been studied in one completed Phase 2 clinical trial with the identifier NCT02126670. This trial evaluated ACT01 in combination with Comp01-04 in patients with actinic keratosis and enrolled 100 participants in the United States. The trial was placebo-controlled and randomized.
No, ACT01 and Comp01-04 are distinct agents. In the clinical trial NCT02126670, ACT01 was studied in combination with Comp01-04, indicating that they are separate drugs used together in the treatment of actinic keratosis.